GRK5 and renal cell carcinoma: Further, Kaplan–Meier survival analysis showed that GRK5 high expression was associated with shorter OS, but not RFS, which is consistent with the previous reports (Jiang et al., 2018; Zhao et al., 2019a) that GRK5 high-expression NSCLC or renal cell carcinoma patients had a worse OS rate than the low-expression patients.